Unknown

Dataset Information

0

Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials.


ABSTRACT: Patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) with deletion 17p [del(17p)] have poor outcomes with chemoimmunotherapy. Ibrutinib is indicated for the treatment of CLL/SLL, including del(17p) CLL/SLL, and allows for treatment without chemotherapy. This integrated analysis was performed to evaluate outcomes in 230 patients with relapsed/refractory del(17p) CLL/SLL from three ibrutinib studies. With a median of 2 prior therapies (range, 1-12), 18% and 79% of evaluable patients had del(11q) or unmutated IGHV, respectively. With a median follow-up of 28 months, overall response rate was 85% and estimated 30-month progression-free and overall survival rates were 57% [95% confidence interval (CI) 50-64] and 69% (95% CI 61-75), respectively. Patients with normal lactate dehydrogenase or no bulky disease had the most favourable survival outcomes. Sustained haematological improvements in haemoglobin, platelet count and absolute neutrophil count occurred in 61%, 67% and 70% of patients with baseline cytopenias, respectively. New onset severe cytopenias and infections decreased in frequency over time. Progression-free and overall survival with ibrutinib surpass those of other therapies for patients with del(17p) CLL/SLL. These results provide further evidence of the robust clinical activity of ibrutinib in difficult-to-treat CLL/SLL populations.

SUBMITTER: Jones J 

PROVIDER: S-EPMC6120509 | biostudies-literature | 2018 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials.

Jones Jeffrey J   Mato Anthony A   Coutre Steven S   Byrd John C JC   Furman Richard R RR   Hillmen Peter P   Osterborg Anders A   Tam Constantine C   Stilgenbauer Stephan S   Wierda William G WG   Heerema Nyla A NA   Eckert Karl K   Clow Fong F   Zhou Cathy C   Chu Alvina D AD   James Danelle F DF   O'Brien Susan M SM  

British journal of haematology 20180605 4


Patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) with deletion 17p [del(17p)] have poor outcomes with chemoimmunotherapy. Ibrutinib is indicated for the treatment of CLL/SLL, including del(17p) CLL/SLL, and allows for treatment without chemotherapy. This integrated analysis was performed to evaluate outcomes in 230 patients with relapsed/refractory del(17p) CLL/SLL from three ibrutinib studies. With a median of 2 prior therapies (range, 1-12), 18% and 79% of evalu  ...[more]

Similar Datasets

| S-EPMC4342187 | biostudies-literature
| S-EPMC6879312 | biostudies-literature
| S-EPMC6093732 | biostudies-literature
| S-EPMC7132223 | biostudies-literature
| S-EPMC6182267 | biostudies-literature
| S-EPMC5921964 | biostudies-literature
| S-EPMC9713021 | biostudies-literature
| S-EPMC6084297 | biostudies-literature
| S-EPMC6510766 | biostudies-literature
| S-EPMC5911578 | biostudies-literature